Nanobiotix : Financial | Nanobiotix announces exercise of warrants by Capital Venture International

0bee7314-a43d-4987-8fa4-bcc47eea4c95.pdf

Small but heading for the big time

Nanobiotix announces exercise of warrants by Capital Venture International Paris, France, Cambridge, MA, USA June 14, 2016 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces that it has received a notification from Capital Ventures International (CVI) to exercise warrants over 50,000 ordinary shares of the Company, at an exercise price of EUR 17.87 per share (par value EUR 0.03 each) representing a share capital increase of an amount, in aggregate, equal to EUR 893,500.

Admission of the new ordinary shares is expected to occur on June 14, 2016 to trading on the regulated market of Euronext in Paris. The new ordinary shares will rank pari passu with the existing ordinary shares.

The 600,000 outstanding warrants hold by CVI may be exercised before the expiration of the warrants on June 30, 2016, as described in the private placement announced on November 25, 2014.

-Ends-

About NANOBIOTIX: www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck Cancer, prostate cancer, rectal cancer (PharmaEngine) and liver cancers (HCC and liver metastases). The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.

Contact

Nanobiotix
Sarah Gaubert Head of Communication and Public Affairs +33 (0)1 40 26 07 55 contact@nanobiotix.com
Media relations
France - NewCap Annie-Florence Loyer +33 (0)6 88 20 35 59 afloyer@newcap.fr	Outside France - Instinctif Partners Melanie Toyne Sewell +44 (0) 207 457 2020 nanobiotix@instinctif.com

Disclaimer

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.